SEC Form 4 · accession 0000886163-17-000085
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles S Berkman
Officer — VP, Gen. Counsel & Secretary
Period of report
Jun 30, 2017
Accepted (ET)
Jul 5, 2017 · 6:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 30, 2017 | J | 243 | $87.125 | A | 43,048 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c).